Adaptimmune
Develops engineered T-cell therapies for people with cancer
Highlights
- New on EvolcAdded 2026-10-29
About Adaptimmune
Adaptimmune is a biotechnology company developing engineered T-cell therapies to treat cancer. Its home page announces the sale of its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to US WorldMeds.
Adaptimmune Limited is based in Abingdon, United Kingdom, and was founded in 2007.
Product: Engineered T-cell cancer therapies, including TECELRA, lete-cel, afami-cel and uza-cel.
Jobs at Adaptimmune
No open positions listed right now.
More biotech & pharma companies
Ads Biotec
Automated laboratory instruments, consumables and purification solutions for cytogenetic, pathology and research labsNew on EvolcAixcell
Autonomous cell culture system running routine and multi-project cell-based workflows for AI/ML data generationNew on EvolcAlimera Sciences
Develops and commercialises ophthalmic medicines for patients with chronic retinal diseasesNew on EvolcAmphista Therapeutics
Develops Targeted Glue protein-degrader medicines for cancer, with a lead acute myeloid leukemia candidate in Phase 1New on EvolcAnanda Pharma
Develops cannabinoid-based medicines for inflammatory pain conditions and heart failureNew on EvolcAndrolabs
Men's health medicines, including testosterone replacement and erectile dysfunction therapies, for patients and healthcare professionalsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- Apache
- Google Analytics 4
- LinkedIn Insight
- X Pixel